FDA steps up counterfeit drug investigations

The FDA Office of Criminal Investigations opened 72 cases concerning counterfeit drugs in 2010, a rise of more than 10 percent over the previous year. In fact, the count has risen for each of the last three years, reports Pharmaceutical Commerce, and it's running three to five times higher than a decade ago.

Some recent counterfeiting activity has involved breaches of the so-called normal chain of distribution. The chain, defined by some states in their pedigree rules, was previously thought safe from external, unregulated activity.

"It's time to reconsider how our country can protect its pharmaceutical supply," says Thomas Kubic, CEO of the Pharmaceutical Security Institute, writing in The Hill. He advocates for Congress to take the lead in the global fight against fake drugs in an editorial supporting recent proposals by the Obama administration and congressional members. The proposals cover IP protection recommendations and stiffer penalties for prescription drug theft.

"Even in a divided political environment," writes Kubic, "it's a commonsense public safety step everyone should be able to support."

- read the story
- here's the op-ed

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.